Centessa Pharmaceuticals (CNTA) Stock Forecast & Price Target

Compare

150 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CNTA Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Centessa

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CNTA Stock 12 Month Forecast

Average Price Target

$32.57

▲(159.94%Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Centessa Pharmaceuticals in the last 3 months. The average price target is $32.57 with a high forecast of $38.00 and a low forecast of $27.00. The average price target represents a 159.94% change from the last price of $12.53.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","15":"$15","23":"$23","31":"$31","39":"$39"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,15,23,31,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.41,15.301538461538462,17.193076923076923,19.084615384615386,20.976153846153846,22.86769230769231,24.75923076923077,26.65076923076923,28.542307692307695,30.433846153846154,32.32538461538462,34.21692307692308,36.10846153846154,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.41,14.883846153846154,16.357692307692307,17.83153846153846,19.305384615384614,20.779230769230768,22.253076923076925,23.72692307692308,25.200769230769232,26.674615384615386,28.14846153846154,29.622307692307693,31.096153846153847,{"y":32.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.41,14.455384615384615,15.500769230769231,16.546153846153846,17.591538461538462,18.636923076923075,19.682307692307692,20.72769230769231,21.77307692307692,22.818461538461538,23.863846153846154,24.909230769230767,25.954615384615384,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.08,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$38.00

Average Price Target$32.57

Lowest Price Target$27.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stacy KuTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/04/25

TD Cowen Reaffirms Their Buy Rating on Centessa Pharmaceuticals (CNTA)

Kelly ShiJefferies

Jefferies

$27

Buy

115.48%

Upside

Reiterated

06/04/25

Centessa Pharmaceuticals: Promising Orexin Drug Pipeline and Strong Market Potential Drive Buy Rating

Ami FadiaNeedham

Needham

$35

Buy

179.33%

Upside

Initiated

05/28/25

Positive Outlook on Centessa Pharmaceuticals Driven by ORX750's Promising Potential and Market Growth

Biren AminPiper Sandler

Piper Sandler

$38

Buy

203.27%

Upside

Reiterated

05/20/25

Centessa Pharmaceuticals (CNTA) Receives a Buy from Piper Sandler

Sean LaamanMorgan Stanley

Morgan Stanley

$27

Buy

115.48%

Upside

Reiterated

05/19/25

Centessa Pharmaceuticals (CNTA) Receives a Buy from Morgan Stanley

Kostas BiliourisBMO Capital

BMO Capital

$35

Buy

179.33%

Upside

Reiterated

05/15/25

Reiterating Our Conviction in CNTA Multi-Billion Dollar Orexin Franchise

David RisingerLeerink Partners

Leerink Partners

$36

Buy

187.31%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (NASDAQ: CNTA), Arcellx Inc (NASDAQ: ACLX) and Belite Bio, Inc. ADR (NASDAQ: BLTE)

Rudy LiChardan Capital

Chardan Capital

$30

Buy

139.43%

Upside

Reiterated

05/14/25

Chardan Capital Reaffirms Their Buy Rating on Centessa Pharmaceuticals (CNTA)

Mayank MamtaniB.Riley Financial

B.Riley Financial

$33

Buy

163.37%

Upside

Reiterated

01/21/25

Analysts Conflicted on These Healthcare Names: Ironwood Pharma (NASDAQ: IRWD) and Centessa Pharmaceuticals (NASDAQ: CNTA)

Debjit ChattopadhyayGuggenheim

Guggenheim

$24→$28

Buy

123.46%

Upside

Reiterated

11/15/24

Centessa price target raised to $28 from $24 at GuggenheimCentessa price target raised to $28 from $24 at Guggenheim

Francois BriseboisOppenheimer

Oppenheimer

$24

Buy

91.54%

Upside

Reiterated

09/26/24

Oppenheimer reiterates Outperform Rating on Centessa Pharmaceuticals (CNTA)Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $24.00 price target on Centessa Pharmaceuticals (NASDAQ: CNTA).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stacy KuTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/04/25

TD Cowen Reaffirms Their Buy Rating on Centessa Pharmaceuticals (CNTA)

Kelly ShiJefferies

Jefferies

$27

Buy

115.48%

Upside

Reiterated

06/04/25

Centessa Pharmaceuticals: Promising Orexin Drug Pipeline and Strong Market Potential Drive Buy Rating

Ami FadiaNeedham

Needham

$35

Buy

179.33%

Upside

Initiated

05/28/25

Positive Outlook on Centessa Pharmaceuticals Driven by ORX750's Promising Potential and Market Growth

Biren AminPiper Sandler

Piper Sandler

$38

Buy

203.27%

Upside

Reiterated

05/20/25

Centessa Pharmaceuticals (CNTA) Receives a Buy from Piper Sandler

Sean LaamanMorgan Stanley

Morgan Stanley

$27

Buy

115.48%

Upside

Reiterated

05/19/25

Centessa Pharmaceuticals (CNTA) Receives a Buy from Morgan Stanley

Kostas BiliourisBMO Capital

BMO Capital

$35

Buy

179.33%

Upside

Reiterated

05/15/25

Reiterating Our Conviction in CNTA Multi-Billion Dollar Orexin Franchise

David RisingerLeerink Partners

Leerink Partners

$36

Buy

187.31%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (NASDAQ: CNTA), Arcellx Inc (NASDAQ: ACLX) and Belite Bio, Inc. ADR (NASDAQ: BLTE)

Rudy LiChardan Capital

Chardan Capital

$30

Buy

139.43%

Upside

Reiterated

05/14/25

Chardan Capital Reaffirms Their Buy Rating on Centessa Pharmaceuticals (CNTA)

Mayank MamtaniB.Riley Financial

B.Riley Financial

$33

Buy

163.37%

Upside

Reiterated

01/21/25

Analysts Conflicted on These Healthcare Names: Ironwood Pharma (NASDAQ: IRWD) and Centessa Pharmaceuticals (NASDAQ: CNTA)

Debjit ChattopadhyayGuggenheim

Guggenheim

$24→$28

Buy

123.46%

Upside

Reiterated

11/15/24

Centessa price target raised to $28 from $24 at GuggenheimCentessa price target raised to $28 from $24 at Guggenheim

Francois BriseboisOppenheimer

Oppenheimer

$24

Buy

91.54%

Upside

Reiterated

09/26/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Centessa Pharmaceuticals

1 Month

xxx

Success Rate

13/20 ratings generated profit

Average Return

+7.41%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +7.41% per trade.

3 Months

xxx

Success Rate

16/20 ratings generated profit

Average Return

+20.91%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +20.91% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

16/20 ratings generated profit

Average Return

+65.53%

reiterated a buy rating 24 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +65.53% per trade.

2 Years

xxx

Success Rate

16/20 ratings generated profit

Average Return

+69.17%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +69.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CNTA Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CNTA has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CNTA average Analyst price target in the past 3 months is 32.57.

Each month's total comprises the sum of three months' worth of ratings.

CNTA Financial Forecast

CNTA Earnings Forecast

Next quarter’s earnings estimate for CNTA is -$0.33 with a range of -$0.37 to -$0.25. The previous quarter’s EPS was -$0.20. CNTA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CNTA has Outperformed its overall industry.

CNTA Sales Forecast

Next quarter’s sales forecast for CNTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $15.06M. CNTA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year CNTA has Outperformed its overall industry.

CNTA Stock Forecast FAQ

What is CNTA’s average 12-month price target, according to analysts?

Based on analyst ratings, Centessa Pharmaceuticals’s 12-month average price target is 32.57.

What is CNTA’s upside potential, based on the analysts’ average price target?

Centessa Pharmaceuticals has 159.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CNTA a Buy, Sell or Hold?

Centessa Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Centessa Pharmaceuticals’s price target?

The average price target for Centessa Pharmaceuticals is 32.57. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $38.00 ,the lowest forecast is $27.00. The average price target represents 159.94% Increase from the current price of $12.53.

What do analysts say about Centessa Pharmaceuticals?

Centessa Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of CNTA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Centessa Pharmaceuticals (CNTA) Stock Forecast & Price Target

CNTA Analyst Ratings

CNTA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Centessa Pharmaceuticals

CNTA Analyst Recommendation Trends

CNTA Financial Forecast

CNTA Earnings Forecast

CNTA Sales Forecast

CNTA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts